key: cord-0736149-damfigmf
authors: Lee, Joo-Youn; Kuo, Chih-Jung; Shin, Jin Soo; Jung, Eunhye; Liang, Po-Huang; Jung, Young-Sik
title: Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library
date: 2021-06-15
journal: Bioorg Med Chem Lett
DOI: 10.1016/j.bmcl.2021.128067
sha: ac42502a637f15d454955d4581df6703d4689a82
doc_id: 736149
cord_uid: damfigmf

The outbreak of coronavirus (CoV) disease 2019 (COVID-19) caused by the severe acute respiratory syndrome CoV-2 (SARS-CoV-2) has turned into a pandemic. The enzyme 3C-like protease (3CL(pro)) is essential for the maturation of viral polyproteins in SARS-CoV-2 and is therefore regarded as a key drug target for treating the disease. To identify 3CL(pro) inhibitors that can suppress SARS-CoV-2 replication, we performed a virtual screening of 500,282 compounds in a Korean compound bank. We then subjected the top computational hits to inhibitory assays against 3CL(pro) in vitro, leading to the identification of a class of non-covalent inhibitors. Among these inhibitors, compound 7 showed an EC(50) of 39.89 μM against SARS-CoV-2 and CC(50) of 453.5 μM. This study provides candidates for the optimization of potent 3CL(pro) inhibitors showing antiviral effects against SARS-CoV-2.

As of January 26, 2021, the coronavirus (CoV) disease 2019 (COVID-19) 1 has caused 99,825,219 confirmed cases and 2,143,198 deaths (https://covid19.who.int/). The first case was reported in December 2019. 1, 2 The causative agent of COVID-19 is homologous to the severe acute respiratory syndrome (SARS)-associated CoV (SARS-CoV) that caused an outbreak in 2002-2003, 3, 4 and it was thereby named SARS-CoV-2 by the World Health

Organization. Another outbreak that occurred in the Middle East in 2012 and spread to South Korea in 2015 was also caused by a human CoV known as the Middle East respiratory syndrome CoV (MERS-CoV). 5, 6 Targeting the enzymes essential for viral replication and the lifecycle of SARS-CoV-2 is a promising strategy for clinical therapy. At present, remdesivir treatment has shown a marginal (68%) benefit in clinical trials for patients with COVID- 19, 7 and it was thereby approved for use by the USA-Food and Drug Administration (FDA). It was previously shown to inhibit SARS-CoV and MERS-CoV, 8 and it also antagonizes SARS-CoV-2 replication at a half-maximal effective concentration (EC 50 ) of 0.7 μM 9 by targeting the viral enzyme RNA-dependent RNA polymerase. 10 A key protease called 3C-like protease (3CL pro ) undergoes autocleavage and then cleaves 11 sites on polyproteins generated by CoVs inside the host cells, which is essential for viral replication 11 ; therefore, it has been used as a target for developing antivirals against SARS-CoV, MERS-CoV, and SARS-CoV-2. 12-14 3CL pro is a chymotrypsin-like enzyme; however, it utilizes the His-Cys catalytic dyad to cleave conserved sequences of (Leu, Met, Phe)-Gln↓(Ser, Ala, Gly) on the polyproteins of SARS-CoV. 15 Due to the essential role of the protease, several rationally designed peptidomimetics based on its substrate specificity, as well as FDA-approved or experimental drugs such as disulfiram, ebselen, tideglusib, TDZD-8, carmofur, and PX12 have been investigated and shown to inhibit 3CL pro activity and SARS-CoV-2 replication. 16−19 Moreover, boceprevir, GC-376, and calpain inhibitors II and 5 XII have been demonstrated to inhibit SARS-CoV-2 viral replication by targeting 3CL pro . 20 As reported recently, the cysteine protease inhibitors MDL-28170 (calpain inhibitor III) and ONO 5334 (cathepsin K inhibitor) inhibit SARS-CoV-2 viral replication. 21 Furthermore, presently used pharmaceuticals and herbal medicines have been screened for activity against SARS-CoV-2; several compounds have been identified as inhibitors of 3CL pro activity and SARS-CoV-2 replication. 22 Moreover, by screening collections of 1068 and 2701 FDA drugs for inhibition of the 3CL pro and papain-like protease, respectively, we identified six drugs showing activity against SARS-CoV-2. 23 Using an artificial intelligence approach, several drugs have been identified that inhibit SARS-CoV-2 replication in vitro. By performing quantitative high-throughput screening of 10,755 approved and investigational drugs and bioactive compounds, 23 small molecules have been found that inhibit SARS-CoV-2 3CL pro activity at a half-maximal inhibitory concentration (IC 50 ) ranging from 0.26 to 28.85 μM, among which seven had an anti-SARS-CoV-2 effect. 24 By analyzing the 3CL pro pharmacophore clusters for application in virtual screening of 2122 FDA drugs, we identified nelfinavir and boceprevir for drug repurposing for treating COVID-19. 25 In this study, we performed virtual screening of the Korea Chemical Bank (KCB) library and identified a group of 3CL pro inhibitors that showed IC 50 values less than 10 µM. Among the inhibitors identified, the most potent candidate showed moderate antiviral activity at an EC 50 of 39.89 µM. Our study provides candidates for inhibiting 3CL pro activity and SARS-CoV-2 replication, which can be optimized further for developing a potential therapy for COVID-19. 6 Virtual screening of the KCB library to identify potential 3CL pro inhibitors. To identify non-peptidomimetic chemical inhibitors of SARS-CoV-2 3CL pro from the KCB library, we performed ligand-based virtual screening using the three-dimensional (3D) shapes of the ligand-complexed SARS-CoV 3CL pro structures, 3MJ5, 3SN8, 3V3M, 4OVZ, 4OW0, and 4TWW, obtained from the Protein Data Bank (PDB) (http://www.rcsb.org). All ligandbased virtual screening was performed using the OpenEye Scientific software (OpenEye Scientific Software, Santa Fe, NM, USA). The database was prepared using OMEGA v3.0.1, which was used to generate a maximum number of 200 low-energy conformers for each molecule in the 500,282-membered KCB library. A 3D shape similarity search of ligands as a query was performed using ROCS v3.2.2, and the top 10,000 hits for each query molecule were selected based on the ROCS_TanimotoCombo score. We then performed a 3D electrostatic properties similarity search for the screened 10,000 compounds using EON v2.2.0, and the top 1,000 hits were selected based on the EON_ET_Combo score for each of the six query molecules. The sum of 3D shape-and electrostatically similar candidates comprised 6,000 compounds that were finally selected for structure-based virtual screening.

Structure-based virtual screening was performed using Schrodinger Suite 2020-1 (Schrödinger LLC, New York, NY, USA) and the X-ray crystal structure of SARS-CoV-2 3CL pro in complex with the peptide inhibitor obtained from PDB (ID 6LU7). The protein structure was modified using Protein Preparation Wizard in Maestro, and the receptor grid box was generated at a cubic size of 25 × 25 × 25 Å centered on a complexed ligand. The 6,000 compounds identified via ligand-based virtual screening and the 500,282 members of the KCB library were subjected to ligand preparation using the LigPrep module by applying an OPLS3e force field. During the process, tautomer and ionization states at pH 7.0 ± 2.0 were generated using the Epik module. Docking for each chemical library database was 7 performed using the Glide v8.6 program in the Standard Precision mode. Based on visual inspection, 253 compounds were selected for performing 3CL pro assays to determine the active hits.

Similarity-based virtual screening using two-dimensional fingerprints. To identify more analogues of the active hits, we performed a second round of virtual screening based on the fingerprint similarity method. The similarity between single pairs of compounds was calculated using Pipeline Pilot 2020 (Dassault Systèmes BIOVIA, San Diego, CA, USA).

The KCB library database was screened using a Tanimoto coefficient ≥ 0.8 compared with the hits for selecting the compounds for IC 50 measurements.

candidate compounds, we next tested their inhibitory activity against 3CL pro using a fluorogenic peptide, Dabcyl-KTSAVLQSGFRKME-Edans, which contains a fluorescence quenching pair; the fluorescence increased when the peptide was cleaved by the protease. 22 Subsequently, the IC 50 values of the active compounds were determined using reaction mixtures containing 2.5 nM 3CL pro and 6 μM fluorogenic substrate in a buffer of 20 mM Bis-Tris (pH 7.0) in the absence and presence of various concentrations of the inhibitors. All experiments were performed in triplicate and the values are presented as the mean ± standard deviation ( Table 1) . The most active were compounds 3 and 7, and their IC 50 values were determined to be 8.0 ± 1.4 and 5.7 ± 1.1 M, respectively. 

Computer modeling of the binding modes of compounds 3 and 7. According to the in silico virtual screening and the 3CL pro inhibition assay, compounds 3 and 7 were identified as the most potent inhibitors in the group. To determine their potential binding modes with 3CL pro , computer modeling was performed for these two compounds. In compound 3 (Fig.   1A) , the triazolopyrimidineone ring was found to bind to the active site adjacent to Cys145 via electrostatic interactions, whereas the Gly143 backbone NH formed additional hydrogen bonds with the nitrogen of the ring. The amide bond formed two hydrogen bonds with the backbone NH groups of Thr26 and Gly143. The 1,4-difluoro substituted phenyl ring was located toward Thr24 and Thr26. The 3,5-dimethyl substituted phenyl group was bound to the hydrophobic pocket formed by His41, Met49, and Met165. In compound 7 (Fig. 1B) , the benzoimidazopyrimidinone ring was found to bind to the active site adjacent to Cys145 via electrostatic interactions. The carbonyl group of the amide bond formed hydrogen bonds with 9 the backbone NH groups of Gly143 and Ser144. The 1,3-difluoro substituted phenyl ring was located toward Leu27 and Met49 and was shorter than the 1,3-difluorophenyl ring in compound 3. The chlorophenyl ring was found to bind to the same hydrophobic pocket that compound 3. Therefore, compound 7 with a selectivity index of more than 10 might serve as an initial hit for further optimization of this group of inhibitors. We thus provide here a candidate for further optimization for potential treatment of COVID-19.

The chemical library used in this study was kindly provided by the Korea Chemical Bank authors also thank the support from KRICT to YSJ and Academia Sinica, Taiwan to PHL.

We declare that we have no conflicts of interest.

To create your abstract, type over the instructions in the template box below. Fonts or abstract dimensions should not be changed or altered. Leave this area blank for abstract info.

Proc. Natl. Proc. Sci. USA. 2021

Osong Public Health Research Perspectives